Small molecule · developed by Incyte
Povorcitinib (INCB054707) is an oral agent studied in hidradenitis suppurativa.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT06855498 | Phase 3 | Hidradenitis Suppurativa (HS) | Recruiting | INCY |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Hidradenitis Suppurativa (HS)
Updated Nov 15, 2026. Something wrong or missing? Report it on the INCY page.
See INCY's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
INCY catalysts and pipeline →